AlphAIAlphAI — Financial news for AI agents
quiverquant.comSEP 151 min read$EYPT

$EYPT stock is down 12% today. Here's what we see in our data.

Eypt stock (EYPT) fell 12% today with $8.78M in trading volume. Insiders traded shares twice in 6 months, with 1 purchase and 1 sale. 89 hedge funds added shares, while 96 reduced positions. Analysts' median price target is $56.0.

Original reporting
quiverquant.com
Published Sep 15, 2026, 7:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
$EYPT stock is down 12% today. Here's what we see in our data. — source image
Source · quiverquant.com
Decision brief

The 30-second read

$EYPTBearishLow
01

Why it matters

Provides a snapshot of recent market activity but lacks a fresh corporate event; useful for short‑term traders monitoring flow.

02

Market read

EYPT's 12% drop highlights immediate trading pressure; no new fundamental news.

03

What to watch

Potential hidden catalyst such as upcoming earnings or regulatory news not yet disclosed.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates recent insider transactions, hedge‑fund holdings changes, and price targets for EYPT.

Company-level read

Ticker impact

$EYPTBearishMedium confidence
Context

Stock fell 12% today with $8.78M volume, accompanied by recent insider trades and hedge‑fund position changes.

Expected impact

Potential further downside if selling persists; watch for support around recent low.

Evidence & confidence

Price move is driven by disclosed trading activity rather than a new corporate event.

Market effects

Sector

Limited; the move reflects company‑specific flow rather than sector trends.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the sell‑off is over‑reacted, a bounce could occur on short‑covering.

Key entities

  • Insider
    Karen L. Zaderej

    Purchased 10,600 shares.

  • Insider
    Ramiro Ribeiro

    Sold 2,437 shares.

Read at source← All news

Related articles

SEP 10
$EYPTMedAI 8/10

EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027

EyePoint posted an updated investor presentation showing LUGANO Phase 3 DURAVYU topline results. While the full dataset did not achieve non-inferiority (NI) due to an asymmetric cohort, ad hoc analysis showed NI in BCVA. DURAVYU reduced treatment burden by 42% and had a favorable safety profile. EyePoint plans to file an NDA for wet AMD in H1 2027, pending positive LUCIA results and pre-NDA FDA engagement in Q4 2026.

tradingview.com1 min
AUG 18
$EYPTHighAI 9/10

EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal

EyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have

tradingview.com5 min
AUG 18
$EYPTMed

EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’

EyePoint Inc. (EYPT) shares fell again in pre-market after a Phase 3 wet AMD trial setback. RBC Capital downgraded EYPT to Sector Perform from Outperform and cut its price target about 86% to $5, citing Duravyu’s failure to meet the primary endpoint versus aflibercept. RBC and H.C. Wainwright said regulatory and clinical uncertainty could persist; results expected in Q4.

tradingview.com4 min
AUG 17
$EYPTHighAI 8/10

EyePoint's DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint; Stock Plunges

EyePoint (EYPT) reported topline Phase 3 LUGANO results for DURAVYU (vorolanib intravitreal insert) in wet AMD. The trial missed the primary endpoint versus aflibercept in the full dataset, but an ad hoc analysis excluding a small cohort showed non-inferiority (p=0.0096). Secondary results included a 42% treatment-burden reduction (p<0.0001). LUCIA data expected Q4 2026.

rttnews.com4 min
AUG 17
$EYPTMed

The Surprising Reason This Biotech Plummeted 69%

EyePoint (EYPT) shares fell about 69% after its Duravyu treatment for wet age-related macular degeneration missed the primary endpoint in a late-stage study, according to the company. Results cited include a 42% reduction in treatment burden and 56% of patients supplement-free by week 56, but the trial did not meet its main goal.

investors.com2 min